As we previously reported, on September 26, 2016, the district court in Janssen v. Celltrion entered partial final judgment that the ’471 patent, asserted by Janssen, was invalid. Today, Janssen filed a notice that they are appealing the district court’s judgment to the Federal Circuit.
Meanwhile, Celltrion’s partner Pfizer announced last week that it will begin shipping Inflectra® (infliximab-dyyb), their FDA-licensed biosimilar of Remicade®, to wholesalers in late November 2016. Also, late last week, Celltrion withdrew its motion to dismiss the ’083 patent (i.e., the sole remaining patent in the case) and instead filed a motion for partial summary judgment of non-infringement of that patent.
Stay tuned to the Big Molecule Watch for further updates and analysis.
